Steven Devine, MD, Discusses Exciting Abstracts From ASH 2021

Video

Steven Devine, MD, spoke about which abstracts he found most interesting at ASH 2021.

At the 2021 American Society of Hematology Annual Meeting, Steven Devine, MD, chief medical officer of the National Marrow Donor Program/Be the Match and associate scientific director for Center for International Blood and Marrow Transplant Research (CIBMTR), discussed abstracts that he found particularly interesting. He started the discussion with the ZUMA-7 trial (NCT03391466), which utilized axicabragene ciloleucel (axi-cel; Yescarta) compared with standard of care in patients with relapsed/refractory large B-cell lymphoma. Patients treated with axi-cel had a significant improvement in event-free survival as well as quality-of-life measures.1,2

Transcript:

The ZUMA-7 abstract that was presented at the plenary session and has been published in the New England Journal of Medicine was potentially practice changing. The point that was made during the plenary session is that we need to do a better job enrolling a diverse set of patients, and this is certainly a message for the blood and marrow transplant field.

From the transplant perspective, there was another CIBMTR analysis looking at the impact of donors and outcomes in patients with lymphoma. We compared haploidentical donors to matched unrelated donors and virtually all outcomes favored the use of matched unrelated donors over haploidentical donors if post-transplant cyclophosphamide is used for graft-versus-host disease prophylaxis. That’s the second study that’s analyzed if post-transplant cyclophosphamide is used, that matched unrelated donor might be favored over haploidentical donor if the unrelated donor is readily available.

References

1. Locke FL, Miklos DB, Jacobson C, et al. Primary Analysis of ZUMA‑7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Presented at the 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Atlanta, GA. Abstract 2. https://bit.ly/33q8RFy

2. Elsawy M, Chavez J, Avivi I, et al. Patient-reported outcomes in a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel (axi-cel) versus standard of care therapy in patients with relapsed/refractory large B-cell lymphoma (ZUMA-7). Presented at the 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Atlanta, GA. Abstract 430.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content